AI for Drug Discovery, Bio-Marker Development and Advanced R&D Landscape Overview 2018 / Q2 - ResearchAndMarkets.com

August 30, 2018

DUBLIN--(BUSINESS WIRE)--Aug 30, 2018--The “AI for Drug Discovery, Bio-Marker Development and Advanced R&D Landscape Overview 2018 / Q2” report has been added to ResearchAndMarkets.com’s offering.

The second quarter of 2018 saw major changes, significant investments, acquisitions, and the establishment of substantial joint ventures. This serves as a stark reminder of how fast the AI for Drug Discovery, Biomarker Development and Advanced R&D sector is advancing. Many trends noted in our last report have continued and intensified, while other new trends have emerged as well.

The report is structured in such a way as to meet the needs of different kinds of readers and stakeholders according to their specific interests and specialisation. It includes both broad chapters that describe the underlying fundamentals of different areas of the AI for Drug Discovery sphere, as well as chapters that give specific attention to industry trends and developments, and chapters that provide comparative analyses of companies, investors, R&D centers, IT, Tech and pharma corporations.

The report begins with several infographic MindMaps that deliver an understanding of the scope of the industry landscape at a single glance, including segmentation (by application and by region) of companies, investors and R&D centers. The report’s Executive Summary charts the major trends and significant developments that have occurred in the industry during the second quarter of 2018. The report’s Introduction (Background and Fundamentals of AI for Drug Discovery) lays the groundwork and background for an understanding of its more specialized chapters, offering a basic introduction to AI in Drug Discovery, the broader AI in healthcare industry, the specific factors that cause resistance to change in the BioPharma industry, and an introduction into the ways in which IT and Tech corporations are entering the sphere of AI in Drug Discovery.

Key Topics Covered:

AI for Drug Discovery Landscape Mind Maps

Executive Summary

Introduction: Background and Fundamentals of AI for Drug Discovery Industry

Section I: AI for Drug Discovery Landscape Overview (Industry Developments Q2 2018)

Chapter I: Landscape of AI for R&D and Drug Discovery Q2 2018

Chapter II: Regional Comparison: USA, UK, EU and Asia-Pacific

Chapter III: Trends of Investment and M&A Deals

Chapter IV: BioPharma Corporations Onboarding AI for Drug Discovery

Chapter V: IT & Tech Corporations Entering the AI for Drug Discovery Space

Chapter VI: Government Initiatives

Chapter VII: Industry-Specific Media & Conferences

Section II: Novel Technologies & Trends (Industry Forecast 2019 2020)

Chapter VIII: Deep Learning in Drug Discovery

Chapter IX: Longevity Research (AI and Advanced R&D)

Chapter X: Next Generation AI, convergence with Blockchain and Digital Medicine

Section III: Comparative Industry Analysis & Classification Framework (Investor and M&A Guide)

Chapter XI: Classification/Ratings of AI for Advanced R&D and Drug Discovery Companies

Chapter XII: 2010-2016 - Investment Rounds, M&A Deals and Notable Events

Chapter XIII: 2017 - Investment Rounds, M&A Deals and Notable Events

Chapter XIV: Q1 2018 - Investment Rounds, M&A Deals and Notable Events

Chapter XV: Q2 2018 - Investment Rounds, M&A Deals and Notable Events

Appendix / Profiles

100 Companies Applying AI for Drug Discovery and Advanced R&D

20 Leading R&D centers

15 BioPharma Corporations Using Artificial Intelligence for Drug Discovery

15 Tech Corporations interested in Advanced AI applications in Healthcare

220 Investors in AI for Drug Discovery

For more information about this report visit https://www.researchandmarkets.com/research/nth668/ai_for_drug?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180830005829/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Biomarkers



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/30/2018 04:23 PM/DISC: 08/30/2018 04:23 PM


Update hourly